Form 4: HCW Biologics Director Acquires Shares Through Convertible Note Conversion

Scott T. Garrett, a director at HCW Biologics, acquired 13,423 shares of common stock through the conversion of unsecured convertible promissory notes.

Summary

• On May 16, 2025, Scott T. Garrett, a director of HCW Biologics Inc., acquired 13,423 shares of common stock.
• The acquisition was a result of the conversion of unsecured convertible promissory notes.
• These notes were part of a $270,000 financing round where one-year notes were issued to six holders.
• The notes had a mandatory conversion provision, converting into common stock at $7.45 per share after the closing of the company's registered offering on May 15, 2025.
• The conversion also included an allocated portion of the 2,174,311 shares of Wugen Inc. common stock held by the company.
• Following the transaction, Garrett directly owns 25,505 shares of HCW Biologics Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a transaction. A director increasing their stake is generally viewed as a positive, but the transaction itself is simply a conversion of debt.

Positives

• A director increasing their stake in the company can be seen as a positive signal.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing investors with insights into the actions of company directors and officers.

Stakeholder Impact

• The conversion of notes into shares dilutes existing shareholders' ownership.

Key Dates

Keywords

HCW Biologics, Director, Share Acquisition, Convertible Notes, Form 4, HCWB, Garrett, Wugen Inc.